Trial Profile
A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Panobinostat (Primary)
- Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- 01 Nov 2021 Results assessing the clinical benefit of the combination of the mTORi, everolimus, and the HDACi, panobinostat,in patients with relapsed or refractory diffuse large b-cell lymphoma, published in the Cancer Investigation.
- 27 Apr 2016 Status changed from active, no longer recruiting to discontinued as toxicity seemed to outweigh the benefit.
- 03 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.